Search Results

. The safety of bevacizumab . Expert Opin Drug Saf 2006 ; 5 : 289 – 301 . 13. Jain RK . Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy . Nat Med 2001 ; 7 : 987 – 989 . 14

,” commented Dr. Borad. Immunotherapy The combination of antiangiogenics with immune checkpoint inhibitors (atezolizumab + bevacizumab) is a recommended option for certain patients. “We know that hepatocellular cancers have a tumor microenvironment in a

According to Dr. Haddad, other research looking at targets besides immunotherapy has been “disappointing.” A long-running phase III trial of chemotherapy with or without bevacizumab in patients with recurrent/metastatic HNSCC showed no statistically

/print certificate. Release date: November 4, 2014; Expiration date: November 4, 2015 Learning Objectives Upon completion of this activity, participants will be able to: Describe the challenges of MRI assessment in patients receiving bevacizumab

erlotinib plus bevacizumab. Response to Gemcitabine-Based Treatments A total of 88% of patients (50/57) who received a gemcitabine-based regimen were evaluable for response ( Table 2 ), including 37 of 41 patients who received gemcitabine

trial. 35 The results of AVAglio and RTOG 0825, 2 studies examining the addition of bevacizumab to radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, were recently presented. 39 , 40 Neither study showed an OS advantage with

to determine benefit from adjuvant chemotherapy; there is a similar lack of data for ‘high-risk’ stage II disease and benefit from adjuvant chemotherapy.” 3 Finally, adding the biologic bevacizumab or cetuximab did not appear to offer an advantage

German GeparSixto study, 1 the inclusion of carboplatin improved the pathologic complete response (pCR) rate compared with paclitaxel, nonpegylated liposomal doxorubicin, and bevacizumab used alone among those patients with triple-negative breast cancer

benefit of adding targeted biologic agents, such as bevacizumab and cetuximab, is being tested. Initial phase I/II trials of bevacizumab plus preoperative 5-FU or capecitabine-based chemoradiation revealed pCR rates of 18% to 24%. 17 , 18 However, more

, interferon alfa, or both for advanced renal-cell carcinoma . N Engl J Med 2007 ; 356 : 2271 – 2281 . 40 Yang JC Haworth L Sherry RM . A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal